




RealRate

PHARMACEUTICAL 2023

Evoked Pharma Inc
Rank 309 of 446





PHARMACEUTICAL 2023

Evoke Pharma Inc
Rank 309 of 446



The relative strengths and weaknesses of Evoke Pharma Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Evoke Pharma Inc compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 43% points. The greatest weakness of Evoke Pharma Inc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 109% points.

The company's Economic Capital Ratio, given in the ranking table, is -12%, being 55% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	11,722
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,655
Liabilities, Non-Current	6,112
Other Assets	129
Other Compr. Net Income	0
Other Expenses	370
Other Liabilities	0
Other Net Income	-438
Other Revenues	2,509
Property and Equipment	0
Research and Development	301
Selling, General and Administrative Expense	9,624

Output Variable	Value in 1000 USD
Assets	11,851
Liabilities	7,767
Expenses	10,295
Revenues	2,509
Stockholders Equity	4,085
Net Income	-8,224
Comprehensive Net Income	-8,224
Economic Capital Ratio	-12%